Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate

被引：8

作者：

Fakhry, Carole ^{[2
]}

Bajaj, Gopal ^{[3
]}

Aygun, Nafi ^{[4
]}

Westra, William ^{[5
]}

Gillison, Maura ^{[1
]}

机构：

[1] Ohio State Univ, Dept Med, Div Hematol & Oncol, Columbus, OH 43210 USA

[2] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD USA

[4] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA

[5] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2012年 / 34卷 / 02期

关键词：

methotrexate; nasopharyngeal carcinoma; leptomeningeal disease; CNS involvement; high-dose methotrexate; NERVOUS-SYSTEM LYMPHOMA; COMBINED-MODALITY THERAPY; PRIMARY CNS LYMPHOMA; NON-HODGKINS-LYMPHOMA; RADIATION-THERAPY; PHASE-II; MENINGEAL CARCINOMATOSIS; INTRATHECAL CHEMOTHERAPY; NEOPLASTIC MENINGITIS; DEFERRED RADIOTHERAPY;

D O I：

10.1002/hed.21516

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Background. Nasopharyngeal carcinoma with leptomeningeal involvement is rare and typically has poor prognosis. Methods and Results. We present a case report of a patient with nasopharyngeal carcinoma who was treated with high-dose intravenous methotrexate and remains asymptomatic and without clinical evidence of disease 6 years later. Conclusions. Systemic high-dose methotrexate should be evaluated in the treatment of advanced nasopharyngeal carcinoma with central nervous involvement. (C) 2010 Wiley Periodicals, Inc. Head Neck 34: 296-300, 2012

引用

页码：296 / 300

页数：5

共 47 条

[1] Long-term survival in primary CNS lymphoma [J].

Abrey, LE ;

DeAngelis, LM ;

Yahalom, J .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :859-863

[2] Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].

Al-Sarraf, M ;

LeBlanc, M ;

Giri, PGS ;

Fu, KK ;

Cooper, J ;

Vuong, T ;

Forastiere, AA ;

Adams, G ;

Sakr, WA ;

Schuller, DE ;

Ensley, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317

[3]

BAKER SR, 1982, CANCER-AM CANCER SOC, V49, P163, DOI 10.1002/1097-0142(19820101)49:1<163::AID-CNCR2820490132>3.0.CO

[4]

2-8

[5]

BALIS FM, 1989, AM J PEDIAT HEMATOL, V11, P74

[6] Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07 [J].

Batchelor, T ;

Carson, K ;

O'Neill, A ;

Grossman, SA ;

Alavi, J ;

New, P ;

Hochberg, F ;

Priet, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1044-1049

[7] LEUKEMOID REACTION, BONE-MARROW INVASION, FEVER OF UNKNOWN ORIGIN, AND METASTATIC PATTERN IN THE NATURAL-HISTORY OF ADVANCED UNDIFFERENTIATED CARCINOMA OF NASOPHARYNGEAL TYPE - A REVIEW OF 255 CONSECUTIVE CASES [J].

CVITKOVIC, E ;

BACHOUCHI, M ;

BOUSSEN, H ;

BUSSON, P ;

ROUSSELET, G ;

MAHJOUBI, R ;

FLORES, P ;

TURSZ, T ;

ARMAND, JP ;

AZLI, N .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2434-2442

[8] COMBINED MODALITY THERAPY FOR PRIMARY CNS LYMPHOMA [J].

DEANGELIS, LM ;

YAHALOM, J ;

THALER, HT ;

KHER, U .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :635-643

[9] Leptomeningeal metastases [J].

Demopoulos A. .

Current Neurology and Neuroscience Reports, 2004, 4 (3) :196-204

[10]

ERVIN TJ, 1981, LARYNGOSCOPE, V91, P1181

← 1 2 3 4 5 →